Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Ranibizumab for CNV in Ocular Histoplasmosis Syndrome
NCT00955630Phase 2Unknown
- Sponsor
- Retina Associates of Kentucky
- Start
- Aug 2009
- Primary completion
- Aug 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in Ocular Histoplasmosis Syndrome (OHS) (2 arms), sponsored by Retina Associates of Kentucky. Primary endpoints: Incidence and severity of ocular adverse events at 1 year and Incidence and severity of other adverse events at 12 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
Ocular Histoplasmosis Syndrome (OHS)
Beyond the preview
Go deeper on NCT00955630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00955630.